Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Conditions: Carcinoma, Non-Small-Cell Lung
Thyroid Neoplasms

First Posted Date: 2022-02-04

Last Posted Date: 2024-02-28

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT05225259

A Study of LY3871801 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3871801

First Posted Date: 2022-02-03

Last Posted Date: 2022-03-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 15

Registration Number: NCT05222399

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: LY3410738
Drug: Itraconazole
Drug: Carbamazepine

First Posted Date: 2022-01-25

Last Posted Date: 2022-12-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 27

Registration Number: NCT05205447

Locations: 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain

Phase 2

Completed

Conditions: Diabetic Peripheral Neuropathic Pain

Interventions: Drug: Placebo
Drug: LY3526318

First Posted Date: 2022-01-04

Last Posted Date: 2023-11-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 155

Registration Number: NCT05177094

Locations: 🇺🇸
Synexus Clinical Research US, Inc - Orlando, The Villages, Florida, United States
🇺🇸
Northwest Clinical Research Center, Bellevue, Washington, United States
🇺🇸
Rainier Clinical Research Center, Renton, Washington, United States

and more 30 locations

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Phase 3

Active, not recruiting

Conditions: Neoplasm Metastasis
Breast Neoplasm

Interventions: Drug: Abemaciclib
Drug: Fulvestrant
Drug: Placebo

First Posted Date: 2021-12-27

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 368

Registration Number: NCT05169567

Locations: 🇨🇳
Taipei Tzu Chi General Hospital, New Taipei City, Taiwan
🇩🇰
Regionshospitalet Gødstrup, Herning, Midtjylland, Denmark
🇭🇺
Bacs-Kiskun Megyei Korhaz, Kecskemét, Bács-Kiskun, Hungary

and more 130 locations

A Study of Two Formulations (Both Refrigerated and Room Temperature) Using an Autoinjector Device in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Sodium chloride
Drug: Citrate buffer
Drug: Mannitol
Device: Prefilled Autoinjector

First Posted Date: 2021-12-13

Last Posted Date: 2022-01-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 44

Registration Number: NCT05154968

Locations: 🇨🇦
Syneos Health, Québec, Canada

A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Phase 4

Completed

Conditions: Migraine
Episodic Migraine

Interventions: Drug: Galcanezumab
Drug: Rimegepant
Drug: Placebo

First Posted Date: 2021-11-19

Last Posted Date: 2024-06-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 580

Registration Number: NCT05127486

Locations: 🇺🇸
Coastal Carolina Research Center, North Charleston, South Carolina, United States
🇺🇸
Gilbert Neurology, Gilbert, Arizona, United States
🇺🇸
California Medical Clinic for Headache and The Los Angeles Headache Center (Research Facility), Los Angeles, California, United States

and more 65 locations

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

Phase 2

Terminated

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: LY3361237
Drug: Placebo

First Posted Date: 2021-11-17

Last Posted Date: 2024-07-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 85

Registration Number: NCT05123586

Locations: 🇺🇸
Atlanta Research Center for Rheumatology, Marietta, Georgia, United States
🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸
Ezy Medical Research, Miami, Florida, United States

and more 44 locations

A Multiple-Dose Study of LY3502970 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3502970

First Posted Date: 2021-11-08

Last Posted Date: 2022-06-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 33

Registration Number: NCT05110794

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

Phase 3

Completed

Conditions: Alzheimer Disease
Mild Cognitive Impairment (MCI)

Interventions: Drug: Donanemab
Drug: Aducanumab

First Posted Date: 2021-11-05

Last Posted Date: 2024-11-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 148

Registration Number: NCT05108922

Locations: 🇺🇸
Neurology Center of North Orange County, Fullerton, California, United States
🇺🇸
Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, United States
🇺🇸
Conquest Research, Winter Park, Florida, United States

and more 27 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy